All Outputs (11)

Long-term survival in a dog with suspected primary nodal plasmacytoma treated with surgical excision (2025)
Journal Article
Figueroa-González, C., Béguin, J., Garty, R., Guillén, A., & Stewart, S. (2025). Long-term survival in a dog with suspected primary nodal plasmacytoma treated with surgical excision. Vet Record Case Reports, https://doi.org/10.1002/vrc2.70072

An 8-year-old Staffordshire bull terrier presented for left submandibular lymphadenopathy. Cytology showed a monomorphic population of mature plasma cells suggestive of plasma cell neoplasia. On physical examination, no other lymphadenomegaly, cutane... Read More about Long-term survival in a dog with suspected primary nodal plasmacytoma treated with surgical excision.

Vinorelbine as a Rescue Treatment for Canine Histiocytic Sarcoma: A Multicentre Retrospective Study of 18 Dogs (2025)
Journal Article
Vigevani, N., Chalfon, C., Guillén, A., Marconato, L., Amores-Fuster, I., Tanis, J., & Finotello, R. (2025). Vinorelbine as a Rescue Treatment for Canine Histiocytic Sarcoma: A Multicentre Retrospective Study of 18 Dogs. Veterinary and Comparative Oncology, https://doi.org/10.1111/vco.13060

Histiocytic sarcoma (HS) is a highly metastatic cancer, and while response to several chemotherapy agents has been studied, the outcome remains poor. Vinorelbine (VNB) has been considered a possible treatment option, but data are limited. The aim of... Read More about Vinorelbine as a Rescue Treatment for Canine Histiocytic Sarcoma: A Multicentre Retrospective Study of 18 Dogs.

Leukemia cutis as a prominent clinical sign in a dog with acute myeloid leukemia (2024)
Journal Article
Rogato, F., Szladovits, B., Martineau, H., Yale, A. D., Mitchell, J. L., Holmes, E. J., Gardner, R. H., & Guillén, A. (in press). Leukemia cutis as a prominent clinical sign in a dog with acute myeloid leukemia. Veterinary Clinical Pathology, https://doi.org/10.1111/vcp.13382

An eight-year-old male neutered crossbreed dog presented with erosive and ulcerative cutaneous lesions in the inguinal regions, the medial aspect of both thighs, and the stifles. Hematologic assessment revealed nonregenerative anemia, thrombocytopeni... Read More about Leukemia cutis as a prominent clinical sign in a dog with acute myeloid leukemia.

Mastocytosis in the skin in dogs: A multicentric case series (2024)
Journal Article
Wyatt, E., Affolter, V., Borio, S., Guillen, A., Verganti, S., Murphy, S., Ballarini, D., Banovic, F., Schmidt, V., & Tanis, J. (2024). Mastocytosis in the skin in dogs: A multicentric case series. Veterinary and Comparative Oncology, https://doi.org/10.1111/vco.12962

Canine cutaneous mastocytosis (CM) is rare in contrast to canine mast cell tumours. In humans, CM commonly affects children and is usually indolent with possible spontaneous resolution. Systemic mastocytosis (SM) with bone marrow involvement typicall... Read More about Mastocytosis in the skin in dogs: A multicentric case series.

Large granular lymphocyte lymphoma in 65 dogs (2005-2023) (2023)
Journal Article
Yale, A., Crawford, A., Gramer, I., Guillen, A., Desmas, I., & Holmes, E. (2023). Large granular lymphocyte lymphoma in 65 dogs (2005-2023). Veterinary and Comparative Oncology, https://doi.org/10.1111/vco.12959

Large granular lymphocyte lymphoma (LGLL) is a rare form of lymphoma in dogs. Limited information exists regarding presentation, treatment response, and outcome. The aim of this single-institute, retrospective study was to characterise clinical prese... Read More about Large granular lymphocyte lymphoma in 65 dogs (2005-2023).

Prognostic factors and outcome in cats with thymic epithelial tumours: 64 cases (1999‐2021) (2023)
Journal Article
Marks, T. A., Rossanese, M., Yale, A. D., Stewart, S., Smallwood, K., Rigas, K., & Guillén, A. (in press). Prognostic factors and outcome in cats with thymic epithelial tumours: 64 cases (1999‐2021). Journal of Small Animal Practice, https://doi.org/10.1111/jsap.13675

Objectives: To describe the clinical presentation, treatment and outcomes of cats diagnosed with thymic epithelial tumours and to determine prognostic factors for survival and recurrence.

Materials and Methods: Clinical records of cats diagnosed w... Read More about Prognostic factors and outcome in cats with thymic epithelial tumours: 64 cases (1999‐2021).

Prevalence of malignancy and factors affecting outcome of cats undergoing splenectomy (2023)
Journal Article
Rossanese, M., Williams, H., De La Puerta, B., Scott, P., Chanoit, G., & Guillén, A. (2023). Prevalence of malignancy and factors affecting outcome of cats undergoing splenectomy. Journal of the American Veterinary Medical Association, 261(11), 1-7. https://doi.org/10.2460/javma.23.05.0258

S plenopathies in cats are uncommonly diagnosed , with a prevalence estimated at 5%, and include primary and metastatic neoplasia, nodu-lar hyperplasia, hematomas, ischemic obstruction and splenitis, among others. 1-4 Splenic diseases are typically i... Read More about Prevalence of malignancy and factors affecting outcome of cats undergoing splenectomy.

Clinical characterisation and long‐term survival of paediatric and juvenile lymphoma in cats: 33 cases (2008‐2022) (2023)
Journal Article
Rogato, F., Tanis, J. B., Pons Gil, B., Pittaway, C., Johnston, C. A., & Guillén, A. (2023). Clinical characterisation and long‐term survival of paediatric and juvenile lymphoma in cats: 33 cases (2008‐2022). Journal of Small Animal Practice, 64(12), 788-796. https://doi.org/10.1111/jsap.13667

Objectives: The aims of this study were to describe the clinical presentation, tumour characteristics, responses to chemotherapy protocols and toxicity in a cohort of cats with lymphoma up to 18 months of age. In addition, the probability of long-ter... Read More about Clinical characterisation and long‐term survival of paediatric and juvenile lymphoma in cats: 33 cases (2008‐2022).

Clinical presentation, treatment and outcome of canine malignant mesothelioma: A retrospective study of 34 cases (2021)
Journal Article
Larsen Moberg, H., Gramer, I., Schofield, I., Blackwood, L., Killick, D., Priestnall, L., & Guillén, A. (2022). Clinical presentation, treatment and outcome of canine malignant mesothelioma: A retrospective study of 34 cases. Veterinary and Comparative Oncology, 20(1), 304-312. https://doi.org/10.1111/vco.12777

Canine malignant mesothelioma (CMM) is a rare and aggressive tumour associated with a poor prognosis. Limited information is available regarding effective treatment options and prognostic factors. The purpose of this retrospective case series was to... Read More about Clinical presentation, treatment and outcome of canine malignant mesothelioma: A retrospective study of 34 cases.

Immunohistochemical expression and prognostic significance of MAGE-A in canine oral malignant melanoma (2021)
Journal Article
Guillén, A., Stiborova, K., Ressel, L., Blackwood, L., Finotello, R., Amores-Fuster, I., Jama, N., & Killick, D. (2021). Immunohistochemical expression and prognostic significance of MAGE-A in canine oral malignant melanoma. Research in Veterinary Science, 137, 226-234. https://doi.org/10.1016/j.rvsc.2021.05.009

Canine oral malignant melanoma (COMM) is considered a chemo-resistant cancer with a poor long-term prognosis. The melanoma-associated antigen A (MAGE-A) genes, which belong to the cancer-testis antigen family, are expressed in several different canin... Read More about Immunohistochemical expression and prognostic significance of MAGE-A in canine oral malignant melanoma.

Molecular pathology in the cancer clinic – where are we now and where are we headed? (2021)
Journal Article
Guillen, A., Smallwood, K., & Killick, D. R. (2021). Molecular pathology in the cancer clinic – where are we now and where are we headed?. Journal of Small Animal Practice, 62(7), 507-520. https://doi.org/10.1111/jsap.13330

Molecular pathology is a developing sub-microscopic discipline of pathology that studies the effects of molecular variations and mutations on disease processes. The ultimate goal of molecular pathology in cancer is to predict risk, facilitate diagnos... Read More about Molecular pathology in the cancer clinic – where are we now and where are we headed?.